Livforsakringsbolaget Skandia Omsesidigt Acquires Shares of 31,800 Phibro Animal Health Corporation $PAHC

Key Points

• Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Phibro Animal Health in the first quarter, purchasing 31,800 shares valued at about $1.76 million. The position represented 0.08% of the company.
• Analysts have become more cautious on PAHC, with recent downgrades and Citigroup cutting its price target from $62 to $44. The stock now carries a consensus rating of Hold with an average target price of $42.50.
• Phibro Animal Health reported better-than-expected quarterly results, earning $0.76 per share on revenue of $383.54 million, and it recently paid a quarterly dividend of $0.12 per share. The company also issued FY 2026 EPS guidance of 2.98 to 3.10.

Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in shares of Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 31,800 shares of the company's stock, valued at approximately $1,759,000. Livforsakringsbolaget Skandia Omsesidigt owned 0.08% of Phibro Animal Health at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in PAHC. Vanguard Group Inc. increased its stake in shares of Phibro Animal Health by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company's stock valued at $57,519,000 after purchasing an additional 13,884 shares in the last quarter. State Street Corp boosted its position in shares of Phibro Animal Health by 5.4% during the fourth quarter. State Street Corp now owns 942,279 shares of the company's stock valued at $35,204,000 after buying an additional 48,243 shares during the last quarter. Millennium Management LLC grew its stake in shares of Phibro Animal Health by 4,227.1% in the fourth quarter. Millennium Management LLC now owns 641,313 shares of the company's stock worth $23,959,000 after acquiring an additional 626,492 shares during the period. Geode Capital Management LLC grew its position in Phibro Animal Health by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 569,111 shares of the company's stock worth $21,265,000 after purchasing an additional 21,951 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in Phibro Animal Health by 1.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 492,335 shares of the company's stock valued at $18,394,000 after acquiring an additional 6,826 shares during the last quarter. Institutional investors own 99.34% of the company's stock.

Analysts Set New Price Targets

PAHC has been the topic of several recent research reports. Zacks Research downgraded shares of Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 21st. Wall Street Zen cut Phibro Animal Health from a "strong-buy" rating to a "buy" rating in a report on Saturday, May 9th. Citigroup dropped their price objective on shares of Phibro Animal Health from $62.00 to $44.00 and set a "neutral" rating for the company in a report on Thursday, May 14th. Finally, Weiss Ratings lowered shares of Phibro Animal Health from a "buy (b-)" rating to a "hold (c+)" rating in a report on Monday, June 15th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $42.50.

Insider Buying and Selling at Phibro Animal Health

In other news, CEO Jack Bendheim sold 4,528 shares of the stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $48.49, for a total transaction of $219,562.72. Following the transaction, the chief executive officer directly owned 56,152 shares in the company, valued at approximately $2,722,810.48. This trade represents a 7.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 39,728 shares of company stock valued at $2,144,299. 50.13% of the stock is currently owned by corporate insiders.

Phibro Animal Health Stock Performance

PAHC stock opened at $33.04 on Wednesday. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of 14.18, a PEG ratio of 0.46 and a beta of 0.46. Phibro Animal Health Corporation has a twelve month low of $25.58 and a twelve month high of $60.08. The business's fifty day simple moving average is $33.45 and its two-hundred day simple moving average is $43.51. The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The company had revenue of $383.54 million during the quarter, compared to analysts' expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Analysts predict that Phibro Animal Health Corporation will post 3.08 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, June 24th. Investors of record on Wednesday, June 3rd were issued a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 1.5%. The ex-dividend date was Wednesday, June 3rd. Phibro Animal Health's payout ratio is presently 20.60%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

Want to see what other hedge funds are holding PAHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.